Delcath Systems heads into its May 7 Q1 earnings call with an elevated short score, a notable European guideline win still fresh in the market's memory, and a week of price weakness that has dragged the stock back toward levels where insiders were buying just two months ago.
The stock closed at $10.21 on April 29, down 3.2% on the day and off nearly 9% over the past week. That reverses a strong prior month — DCTH was up 14% on a 30-day basis before this week's slide. The pullback has been broad across the peer group: PRCT fell 13.5% on the week and CBLL dropped 9.8%, so the move in DCTH is not dramatically out of step with small-cap medtech names in the current environment.
The short positioning here is genuinely elevated. Short interest runs at 11.1% of free float — a level that keeps the stock on the radar for squeeze dynamics. The reading has edged modestly lower over the past month, down roughly 10% in share terms from late March highs, but it ticked back up 0.9% on April 28 after dipping earlier in the week. Days to cover from official FINRA data are at 13.8 days, leaving a meaningful unwind time for a stock this size. The ORTEX short score has held in the mid-70s all month and printed 75.1 on April 28 — near its recent peak — placing DCTH in the second percentile of its universe on short score rank. Borrow availability is not particularly tight: the lending pool is not squeezed, with cost to borrow running at just 0.63% annualised, well off the 1.49% peak seen in early April, and down 23% over the week. There is ample supply for new shorts to enter if sentiment deteriorates.
Options tell a more relaxed story. The put/call ratio is 0.40, fractionally below its 20-day average of 0.41 and sitting near the lower end of its year range of 0.18 to 0.50. The z-score is a mild -0.9 — options traders are not scrambling for downside protection ahead of the print. That relative calm diverges from the elevated short score, and the contrast is worth tracking into May 7.
The Street remains broadly constructive but has been trimming ambitions. The analyst consensus sits at "Moderate Buy" with a consensus target of $22.50, implying roughly 120% upside from current levels. The most recent move on record was BTIG lowering its target to $19 from $23 in late February, following Q4 results that disappointed on site activations. The bull case rests on Hepzato procedure volumes growing 140% through 2025 and a cash balance approaching $91 million, supporting runway through the commercial ramp. The bear case centres on the revenue guidance cut — the company trimmed its full-year forecast to $83-85 million from $93-96 million — citing a slower patient starts pace and Medicaid rebate headwinds. A meaningful macro catalyst arrived in early April: DCTH's CHEMOSAT M-PHP system was included in the 2026 ESMO-EURACAN clinical practice guidelines for uveal melanoma, a recognition that could support European adoption and feed the bull case on indication expansion. The stock rallied on that news; the subsequent 9% pullback this week unwinds most of that gain.
Insider conviction has been steady and consistent. CEO Gerard Michel bought $100,300 worth of shares in early March around $8.96, and CFO Sandra Pennell added $50,000 worth days later at $9.04. Both purchases were at prices well below the current level. Michel has been a repeat buyer since late 2023, building a pattern of open-market purchases at successive price points. The net insider flow over the 90-day window was $150,000, all purchases, no sales. That kind of consistent executive buying into weakness is a data point worth noting as the stock approaches its first-quarter report.
The recent earnings history is worth framing. The February 26 print delivered a -12.8% one-day move and the stock was still down 11% five days later. The March 27 event — likely a secondary release or update — produced a smaller -2.6% one-day move but then recovered, ending up 6.2% by the five-day mark. That pattern suggests the initial reaction to bad news has been sharp, though the five-day recovery can be meaningful if the selloff is overdone. The May 7 call is the first clean Q1 read, and the key variable is whether new patient start trends have stabilised after the summer softness that drove the guidance cut.
The next week is therefore less about whether Hepzato adoption is growing — it demonstrably is — and more about whether the pace of new site activations has recovered enough to justify any reversal of that guidance cut.
See the live data behind this article on ORTEX.
Open DCTH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
